Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of INO-4800 in healthy adults and elderly volunteers
ChiCTR2000040146Phase 2Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INO-4800 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: All adverse events after each vaccination, Binding antibody geometric mean titer and 1 more. Started Dec 2020; status: completed.
02
Drugs
INO-4800
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000040146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040146.